PROCEPT BioRobotics Corp. (NASDAQ:PRCT) is one of the 10 best robotics and automation stocks to invest in.
On May 28, PROCEPT BioRobotics Corp. (NASDAQ:PRCT) disclosed two significant accomplishments in its WATER IV prostate cancer clinical program. Firstly, the company received FDA approval for an Investigational Device Exemption for the second randomized study to evaluate Aquablation therapy against active surveillance. Secondly, the firm finished patient enrollment in the randomized WATER IV trial comparing Aquablation therapy with radical prostatectomy.
everything possible/Shutterstock.com
Aquablation treatment and radical prostatectomy, the accepted surgical standard of care, were compared in the first randomized WATER IV trial, which included 280 intended patients. The company anticipates presenting the WATER IV RP primary endpoint data at the American Urological Association (AUA) Annual Meeting during the spring of 2027.
In order to assess the chronic experience of males with prostate cancer, both randomized WATER IV procedures will track patients for ten years. Over time, the trials will evaluate life quality and control of the disease, including how therapy affects sexual, urinary, and general functions. The company’s ongoing dedication to advancing research and innovation in prostate treatment is demonstrated by the fact that no other prostate cancer medication has been assessed with such thoroughness early in its development.
Later on June 11, the stock was downgraded by Leerink from Outperform to Market Perform, with a target price of $29. This translates into an upside potential of over 33%.
PROCEPT Biorobotics Corp. (NASDAQ:PRCT) is a surgical robotics company focusing on robotic treatments for male urological health. Through their flagship offering, Aquablation® therapy, they amalgamate technology and medical advancements to offer personalized care and improved health for men. The company is committed to revolutionizing benign prostatic hyperplasia (BPH) treatments.
While we acknowledge the risk and potential of PRCT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PRCT and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Follow Insider Monkey on Google News.
Hedge Fund Resource Center